Clinicopathologic Spectrum of Pediatric Posttransplant Lymphoproliferative Diseases Following Solid Organ Transplant.

Jinjun Cheng, Birte Wistinghausen
{"title":"Clinicopathologic Spectrum of Pediatric Posttransplant Lymphoproliferative Diseases Following Solid Organ Transplant.","authors":"Jinjun Cheng, Birte Wistinghausen","doi":"10.5858/arpa.2023-0323-RA","DOIUrl":null,"url":null,"abstract":"<p><strong>Context.—: </strong>Posttransplant lymphoproliferative disorder (PTLD) remains a significant complication in pediatric patients undergoing solid organ transplant (SOT). The majority involve Epstein-Barr virus (EBV)-driven CD20+ B-cell proliferations, which respond to reduction of immunosuppression and anti-CD20-directed immunotherapy. Owing to the low overall incidence, prospective studies of pediatric PTLD are scarce, leading to a lack of comprehensive understanding of this disorder in pediatric populations. This review aims to bridge this knowledge gap by providing a comprehensive analysis of the clinical, morphologic, and molecular genetic features of PTLD in children, adolescents, and young adults after SOT.</p><p><strong>Objective.—: </strong>To examine the clinical features, pathogenesis, and classification of pediatric PTLDs after SOT.</p><p><strong>Data sources.—: </strong>Personal experiences and published works in PubMed.</p><p><strong>Conclusions.—: </strong>PTLD includes a broad and heterogeneous spectrum of disorders, ranging from nonmalignant lymphoproliferations to lymphomas. While most pediatric PTLDs are EBV+, an increasing number of EBV- PTLDs have been recognized. The pathologic classification of PTLDs has evolved in recent decades, reflecting advancements in understanding the underlying pathobiology. Nevertheless, there remains a great need for further research to elucidate the biology, identify patients at higher risk for aggressive disease, and establish optimal treatment strategies for relapsed/refractory disease.</p>","PeriodicalId":93883,"journal":{"name":"Archives of pathology & laboratory medicine","volume":" ","pages":"1052-1062"},"PeriodicalIF":0.0000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archives of pathology & laboratory medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5858/arpa.2023-0323-RA","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Context.—: Posttransplant lymphoproliferative disorder (PTLD) remains a significant complication in pediatric patients undergoing solid organ transplant (SOT). The majority involve Epstein-Barr virus (EBV)-driven CD20+ B-cell proliferations, which respond to reduction of immunosuppression and anti-CD20-directed immunotherapy. Owing to the low overall incidence, prospective studies of pediatric PTLD are scarce, leading to a lack of comprehensive understanding of this disorder in pediatric populations. This review aims to bridge this knowledge gap by providing a comprehensive analysis of the clinical, morphologic, and molecular genetic features of PTLD in children, adolescents, and young adults after SOT.

Objective.—: To examine the clinical features, pathogenesis, and classification of pediatric PTLDs after SOT.

Data sources.—: Personal experiences and published works in PubMed.

Conclusions.—: PTLD includes a broad and heterogeneous spectrum of disorders, ranging from nonmalignant lymphoproliferations to lymphomas. While most pediatric PTLDs are EBV+, an increasing number of EBV- PTLDs have been recognized. The pathologic classification of PTLDs has evolved in recent decades, reflecting advancements in understanding the underlying pathobiology. Nevertheless, there remains a great need for further research to elucidate the biology, identify patients at higher risk for aggressive disease, and establish optimal treatment strategies for relapsed/refractory disease.

小儿实体器官移植后淋巴组织增生性疾病的临床病理学特征。
背景移植后淋巴组织增生性疾病(PTLD)仍然是接受实体器官移植(SOT)的儿童患者的一个重要并发症。大多数淋巴组织增生性疾病是由爱泼斯坦-巴氏病毒(EBV)驱动的CD20+B细胞增生引起的,免疫抑制的减少和抗CD20导向的免疫疗法对其有反应。由于总体发病率较低,有关儿科 PTLD 的前瞻性研究很少,导致人们对儿科人群中的这种疾病缺乏全面的了解。本综述旨在全面分析SOT术后儿童、青少年和年轻成人PTLD的临床、形态学和分子遗传学特征,从而弥补这一知识空白:研究 SOT 后小儿 PTLD 的临床特征、发病机制和分类:个人经验和在PubMed上发表的作品:PTLD包括从非恶性淋巴细胞增生到淋巴瘤等多种不同类型的疾病。虽然大多数儿科 PTLD 为 EBV+,但越来越多的 EBV- PTLD 已被发现。近几十年来,PTLD 的病理分类不断发展,反映了人们对其潜在病理生物学认识的进步。尽管如此,我们仍然亟需开展进一步的研究,以阐明其生物学特性、识别侵袭性疾病风险较高的患者,并为复发/难治性疾病制定最佳治疗策略。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信